Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 447, 512-513 (31 May 2007) | doi:10.1038/447512a; Published online 30 May 2007
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Instrumentation Engineer
- Praj Matrix - Praj Industries Ltd
- Pune, Maharashtra Pune-411021 India
Paleobiologist / Biogeochemist
- University of Cincinnati
- Cincinnati, Ohio, USA
Weighing up the evidence
Heidi Ledford
Abstract
A meta-analysis of clinical trials for the diabetes drug Avandia has hinted at possible cardiovascular risks; but how clear is the study, and how should meta-analyses be viewed against clinical trials?
The day after concerns about Avandia hit the news, the emergency room at New York City's Bellevue Hospital was even more hectic than usual. Patients with diabetes filed in and asked to discontinue their medication while the phone rang with calls from other Avandia users.
To read this story in full you will need to login or make a payment (see right).
